Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 24 | -0.49 Decreased by -6.52% | -0.39 Decreased by -25.64% |
| May 14, 24 | -2.51 Decreased by -617.14% | -0.69 Decreased by -263.77% |
| Mar 28, 24 | -4.22 Decreased by -559.37% | -0.28 Decreased by -1.41 K% |
| Nov 9, 23 | -0.36 Increased by +52.00% | -0.17 Decreased by -111.76% |
| Aug 9, 23 | -0.46 Increased by +37.84% | -0.16 Decreased by -187.50% |
| May 5, 23 | -0.35 Increased by +63.54% | 0.59 Decreased by -159.32% |
| Mar 16, 23 | -0.64 Increased by +5.88% | -0.67 Increased by +4.48% |
| Nov 14, 22 | -0.75 Decreased by -15.38% | -0.76 Increased by +1.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 2.36 M Decreased by -44.55% | -36.12 M Decreased by -550.03% | Decreased by -1.53 K% Decreased by -1.07 K% |
| Mar 31, 24 | 1.03 M Decreased by -56.47% | -129.49 M Decreased by -3.08 K% | Decreased by -12.58 K% Decreased by -7.21 K% |
| Dec 31, 23 | 3.83 M Increased by +N/A% | -92.63 M Decreased by -1.00 K% | Decreased by -2.42 K% Decreased by N/A% |
| Sep 30, 23 | 3.56 M Increased by +N/A% | -4.34 M Increased by +49.07% | Decreased by -121.88% Decreased by N/A% |
| Jun 30, 23 | 4.26 M Increased by +N/A% | -5.56 M Increased by +37.72% | Decreased by -130.35% Decreased by N/A% |
| Mar 31, 23 | 2.36 M Increased by +N/A% | -4.07 M Increased by +65.08% | Decreased by -172.12% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -8.40 M Decreased by -7.03% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -8.53 M Decreased by -10.52% | Decreased by N/A% Decreased by N/A% |